Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis

Miltefosine shows superior early response and a safer systemic profile. However, the certainty of evidence, as assessed by GRADE, ranged from very low to high across outcomes, and long-term data remain limited, highlighting the need for further high-quality studies with extended follow-up.